ImmunoVec
ImmunoVec, Inc.
At ImmunoVec, we develop in vivo therapies to precisely engineer any targeted cell type within the human body.
immunovec.com · Los Angeles, CA
Funding event
The round itself, as filedInferred stageSeries A
Sold of offered$12.7M of $15.0M
Filed2026-07-14
Days since filing82
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-06-29
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Ryan WongExecutive Officer · Director
- William WoodwardExecutive Officer · Director
- Douglass LorenzenExecutive Officer · Director · Promoter
- Chris LucasDirector
Health flags
Three flags, each with the raw inputs behind it · as of 2026-10-03UndersubscribedNot flagged84.7% sold3.2 months since first sale
Prior raiseNot flaggedPrior raise not known—
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-09-243
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
- Senior ScientistOCT 1In Vivo · open 3 days
- Director of Business DevelopmentOCT 1Strategy & Operations · open 3 days
- Computational ScientistOCT 1DNA & Protein Engineering · open 3 days
Also raised in Health & bio
Same sector, 28 days to 2026-10-04Altay TherapeuticsSeries A · $15.7M of $45.1M · San Carlos, CAQuietCarebilitySeries A · $8.8M of $8.8M · Richardson, TXQuiet
75 rounds in Health & bio in the 28 days to 2026-10-03, against 71 in the 28 days before.